Cirrhosis of the liver by Yabluchansky, M. et al.

Supportive module 2: Basics of diagnosis, treatment 
and prevention of major gastroenterological diseases
Cirrhosis of the Liver
LECTURE IN INTERNAL MEDICINE FOR IV COURSE STUDENTS
M. Yabluchansky, L. Bogun, L. Martymianova, O. Bychkova, N. Lysenko, N. Makienko
V.N. Karazin National University Medical School’  Internal Medicine Dept.
Plan of the Lecture 
• Definition
• Epidemiology
• Risk Factors  and Etiology
• Mechanisms 
• Classification
• Clinical presentation
• Diagnosis
• Treatment 
• Prognosis
• Prophylaxis
• Abbreviations
• Diagnostic guidelines
http://www.hepatitisc.uw.edu/process.php?action=getDoc&ID=33&name.jpg
Definition
Cirrhosis is the final histological pathway for a wide variety of liver 
diseases characterized by fibrosis and the conversion of normal liver 
architecture into structurally abnormal nodules that leads to portal 
hypertension, hepatic encephalopathy, and liver cancer with very 
variable progression  from over weeks to many years.
http://patient.info/doctor/cirrhosis-pro
Epidemiology
• Cirrhosis is the ninth leading cause of death in the United States and 
is responsible for 1.2% of all US deaths
• Many patients die in their fifth or sixth decade of life 
• The prevalence is higher in non-Hispanic blacks and Mexican 
Americans, those living below the poverty level, and those with less 
than a 12th grade education
• Each year, 2000 additional deaths are attributed to fulminant hepatic 
failure (FHF), that may be caused viral hepatitis, drugs (e.g., 
acetaminophen), toxins (e.g., Amanita phalloides, the yellow death-
cap mushroom), autoimmune hepatitis, Wilson disease, or a variety 
of less common etiologies. Cryptogenic causes are responsible for 
one third of fulminant cases.  
http://emedicine.medscape.com/article/185856-overview#a3
Epidemiology
https ://static-content.springer.com/esm/art%3A10.1186%2Fs12916-014-0145-y/MediaObjects/12916_2014_145_MOESM15_ESM.gif
Liver cirrhosis mortality in 187 countries between 1980 and 2010: a 
systematic analysis.
Risk Factors and Etiology
• Hepatitis C, B, B+D, 
• Alcoholic liver disease
• Cryptogenic 
• Autoimmune hepatitis
• Biliary cirrhosis and primary sclerosing cholangitis
• Hemochromatosis, Wilson disease, alpha-1 antitrypsin deficiency
• Granulomatous disease (e.g., sarcoidosis)
• Type IV glycogen storage disease
• Drug-induced liver disease (methotrexate, amiodarone, etc.)
• Venous outflow obstruction (Budd-Chiari syndrome, etc.)
• Congestive heart failure 
• Male sex, age >50, regular (moderate) alcohol consumption
file:///C:/Users/asus/Downloads/JJM_Issue_14,_267-272.pdf
Risk Factors and Etiology
http://www.mdpi.com/1422-0067/15/5/7500/htm
Non-alcoholic fatty liver disease (NAFLD).
Mechanism
• Liver cirrhosis is the final pathological result of various chronic liver 
diseases, and fibrosis is the precursor of cirrhosis
• Many types of cells, cytokines and miRNAs are involved in the 
initiation and progression of liver fibrosis and cirrhosis
• Activation of hepatic stellate cells (HSCs) is a pivotal event in fibrosis 
• Defenestration and capillarization of liver sinusoidal endothelial cells 
are major contributing factors to hepatic dysfunction in liver cirrhosis 
• Activated Kupffer cells destroy hepatocytes and stimulate the 
activation of HSCs
• Repeated cycles of apoptosis and regeneration of hepatocytes 
contribute to pathogenesis of cirrhosis 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064077/
Mechanism
• At the molecular level, many cytokines are involved in mediation of 
signaling pathways that regulate activation of HSCs and fibrogenesis
• Recently, miRNAs as a post-transcriptional regulator have been found 
to play a key role in fibrosis and cirrhosis
• Robust animal models of liver fibrosis and cirrhosis, as well as the 
recently identified critical cellular and molecular factors involved in 
the development of liver fibrosis and cirrhosis will facilitate the 
development of more effective therapeutic approaches for these 
conditions.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064077/
Mechanism
http://www.medscape.com/viewarticle/573027
Formal pathogenesis of liver fibrogenesis.
Mechanism
http://www.nature.com/nrc/journal/v6/n9/images/nrc1934-f2.jpg
Mechanism
http://perspectives.galectintherapeutics.com/wp-content/uploads/2016/02/Screen-Shot-2016-02-22-at-8.07.39-AM.png
Portal hypertension.
Mechanism
http://images.slideplayer.com/20/6056890/slides/slide_67.jpg
Portosystemic fnastomosis.
Classification 
International Classification of Diseases  
https ://www.tsoshop.co.uk/productimages/default.aspx?ISBN=9789241549165&FORMAT=3  http://apps.who.int/classifications/icd10/browse/2016/en#/XI
XI Diseases of the digestive
K70.3Alcoholic cirrhosis of liver
K71.7Toxic liver disease with fibrosis 
and cirrhosis of liver
K74 Fibrosis and cirrhosis of liver
K74.3Primary biliary cirrhosis
K74.4Secondary biliary cirrhosis
K74.5Biliary cirrhosis, unspecified
K74.6Other and unspecified cirrhosis of 
liver.
Classification
World Health Organization (Anthony P.P. et al. J Clin Pathol 31:395,1978) 
• Morphologic: macronodular, micronodular, mixed 
• Histologic: portal, post-necrotic, post hepatitis, biliary, congestive 
• Etiologic agents: genetic (i.e. biliary atresia, cystic fibrosis, Wilson 
Disease), toxic, infectious, biliary, vascular (i.e. congestive heart 
failure), cryptogenic (which the cause is unknown), fatty liver.
meddean.luc.edu/lumen/MedED/orfpath/cirhosis.htm 
Classification
http://depts.washington.edu/hepstudy/definitions/uploads/18/Child_Pugh_Turcotte.png
Symptoms
• Decreased appetite 
• Edema
• Ascites
• Easy bruising
• Poor concentration and memory
• Bleeding esophageal varices
• Spontaneous bacterial peritonitis
• Weight loss
• Anorexia
• Weakness
• Impotence
• Gynecomastia.
https://en.wikipedia.org/wiki/Cirrhosis healthline.com/health/cirrhosis#Symptoms4 patient.info/doctor/cirrhosis-pro
Signs                                                       
Cutaneous Features
• Jaundice
• Scratch marks secondary to pruritus
• Spider angiomata/naevi (mainly found on the trunk and face)
• Skin telangiectasia's ('paper money skin')
• Palmar erythema
• Bruising
• Petechia or purpura
• Hair loss
• White nails (sign of hypoalbuminemia)
• Finger clubbing
• Dupuytren's contracture
http://patient.info/doctor/cirrhosis-pro
Signs                                                         
Other Features
• Hepatomegaly and a nodular liver
• Edema
• Gynecomastia and male hair loss pattern
• Hypogonadism/testicular atrophy/amenorrhoea (due to the direct 
toxic effect of alcohol in alcoholic cirrhosis or iron in 
haemochromatosis)
• Kayser-Fleischer ring (a brown-green ring of copper deposit around 
the cornea, pathognomonic for Wilson's disease).
http://patient.info/doctor/cirrhosis-pro
Signs 
Portal Hypertension  
• Hepatic venous pressure gradient (HVPG) greater than or equal to 
5mm Hg and is considered to be clinically significant when HVPG 
exceeds 10 to 12 mm Hg
• The main symptoms and complications: ascites (an accumulation of 
fluid in the abdomen, can be detected clinically when ≥1.5 litres of 
fluid is present); dilated veins in the anterior abdominal wall (caput 
medusae, when veins seen radiating from the umbilicus); 
encephalopathy or confusion and forgetfulness caused by poor liver 
function;  splenomegaly; reduced levels of platelets or white blood 
cells; gastrointestinal bleeding marked by black, tarry stools or blood 
in the stools, or vomiting of blood due to the spontaneous rupture 
and hemorrhage from varices.
webmd.com/digestive-disorders/digestive-diseases-portalen.wikipedia.org/wiki/Portal_hypertension patient.info/doctor/cirrhosis-pro
Signs 
Hepatic Encephalopathy
• Asterixis ('flapping tremor'); suggests hepatic encephalopathy
• To detect asterixis, take the patient's hand and gently hyperextend 
the wrist and joints of the hand, pushing gently on the tips of the four 
fingers
• Ignore the thumb
• Hold that position for several seconds and you will feel a slow, clonic 
flexion-relaxation movement against your hand if asterixis is present.
http://patient.info/doctor/cirrhosis-pro
Clinical Presentation
• Up to 40% of people with cirrhosis may be asymptomatic
• Blood testing for other reasons may reveal abnormal liver function 
and prompt further investigation which shows cirrhosis 
• Initial clinical presentation of patients with decompensated cirrhosis 
is still common and is characterized by the presence of dramatic and 
life-threatening complications, such as variceal hemorrhage, ascites, 
spontaneous bacterial peritonitis, or hepatic encephalopathy.
ncbi.nlm.nih.gov/pmc/articles/PMC2271178/  patient.info/doctor/cirrhosis-pro
Clinical Presentation                          
Activity Grades  
• Inactive: no inflammation and intact limiting plates around septa 
which are fibrotic
• Slight: mild inflammation; segmental erosion of limiting plates
• Moderate: moderate inflammation and damage of limiting plates
• Severe: marked inflammation, extensive damage of limiting plates, 
piecemeal necrosis and parenchymal damage (necrosis, cholestasis, 
dysplasia, malignant transformation.
meddean.luc.edu/lumen/MedED/orfpath/cirhosis.htm   ncbi.nlm.nih.gov/pmc/articles/PMC2271178/  patient.info/doctor/cirrhosis-pro
Clinical Presentation
Decompensation  
• In patients with previously stable cirrhosis, decompensation may 
occur due to various causes, such as constipation, infection (of any 
source), increased alcohol intake, medication, bleeding from 
esophageal varices or dehydration
• Patients with decompensated cirrhosis generally require admission to 
hospital, with close monitoring of the fluid balance, mental status, 
and emphasis on adequate nutrition and medical treatment.   
en.wikipedia.org/wiki/Cirrhosis 
Complications
http://patient.info/doctor/cirrhosis-pro
• Anemia, thrombocytopenia and coagulopathy (folate deficiency, 
hemolysis, hypersplenism, cholestasis) 
• Esophageal varices (portal hypertension)
• Ascites
• Spontaneous bacterial peritonitis  
• Hepatocellular carcinoma    
• Cirrhotic cardiomyopathy  
• Hepatopulmonary syndrome  
• Portopulmonary hypertension.
Diagnosis
• The gold standard for diagnosis of cirrhosis is a liver biopsy, through 
a percutaneous, transjugular, laparoscopic, or fine-needle approach
• A biopsy is not necessary if the clinical, laboratory, and radiologic 
data suggests cirrhosis
• Furthermore, there is a small but significant risk to liver biopsy, and 
cirrhosis itself predisposes for complications caused by liver biopsy
• The best predictors of cirrhosis are ascites, platelet count 
<160,000/mm3, spider angiomata, and Bonacini cirrhosis 
discriminant score greater than 7.
https://en.wikipedia.org/wiki/Cirrhosis#Pathophysiology
Diagnosis                                             
Laboratory Testing   
emedicine.medscape.com/article/182098-overview 
• Complete blood count and liver disease–associated blood tests (e.g., 
aspartate aminotransferase [AST], alanine aminotransferase [ALT], 
bilirubin, alkaline phosphatase [ALP])
• Coagulation tests (prothrombin time [PT], partial thromboplastin 
time [PTT], international normalized ratio [INR])
• Albumin: hypoalbuminemia (impaired hepatic synthetic function)
• Blood urea nitrogen, creatinine, and electrolytes
• Arterial blood gas (ABG) and pH measurements
• Hepatic and viral hepatitis serologies, antinuclear antibody, 
antimitochondrial antibody, antismooth muscle antibody
• Iron indices, alpha1-antitrypsin deficiency, ceruloplasmin, 24-hour 
urinary copper.
Diagnosis                                             
Imaging Studies  
intechopen.com/source/html/18256/media/image35.jpg emedicine.medscape.com/article/182098-overview
Duplex Doppler 
ultrasonography of the liver and 
upper abdomen
Computed tomography (CT) 
scanning and/or magnetic 
resonance imaging (MRI): Can 
be used when ultrasonographic 
findings are inconclusive
Bleeding scan or angiography: 
Used when bleeding is obscure 
and the source is unclear.
Diagnosis                                            
Procedures
emedicine.medscape.com/article/182098-overview 
• Liver biopsy and histologic 
examination
• Hemodynamic measurement of 
the hepatic venous pressure 
gradient (HVPG): A criterion 
standard for assessment of 
portal hypertension
• Upper GI endoscopy (or, 
esophagogastroduodenoscopy 
[EGD]): A criterion standard for 
assessment of portal 
hypertension.  
Diagnosis                                             
Histopathologic Features   
https://www.pathology.med.umich.edu/greensonlab/severechronhep.jpg
Diagnosis                                             
Morphological Type   
https://upload.wikimedia.org/wikipedia/commons/thumb/9/94/Cirrhosis_high_mag.jpg/440px-Cirrhosis_high_mag.jpg 
meddean.luc.edu/lumen/meded/orfpath/images/fig78x.jpgpathology.med.umich.edu/greensonlab/severechronhep.jpg
• Micronodular < 3 mm
• Macronodular > 3 mm
• Mixed
Diagnosis                             
West Haven Criteria Grading System of Hepatic 
Encephalopathy  
aafp.org/afp/2011/1215/p1353.html 
Grade Description
1
Trivial lack of awareness; euphoria or anxiety; shortened 
attention span; impaired performance of addition or subtraction
2
Lethargy or apathy; minimal disorientation for time or place; 
subtle personality change; inappropriate behavior
3
Somnolence to semistupor, but responsive to verbal stimuli; 
confusion; gross disorientation
4 Coma (unresponsive to verbal or noxious stimuli)
Management
• A healthy diet is encouraged, as cirrhosis may be an energy-
consuming process
• Antibiotics are prescribed for infections, and various medications can 
help with itching
• Laxatives, such as lactulose, decrease risk of constipation
• Alcoholic cirrhosis is treated by abstaining from alcohol
• Treatment for hepatitis-related cirrhosis involves medications used to 
treat the different types of hepatitis
• Cirrhosis caused by Wilson's disease is treated with chelation 
therapy (penicillamine) to remove the copper
• Vaccination of susceptible patients should be considered for Hepatitis 
A and Hepatitis B.
https://en.wikipedia.org/wiki/Cirrhosis
Management                                             
Nutrition
• Malnutrition occurs up to 60% of patients, and guidelines recommend 
a daily protein intake of 1.0 to 1.5 g per kilogram of dry body weight
• High-protein diets are well tolerated and are associated with 
sustained improvement in mental status, whereas restriction of 
protein intake does not have any beneficial effect in patients with 
acute hepatic encephalopathy 
• Late-evening meals may improve nitrogen balance without 
exacerbating hepatic encephalopathy
• A 2000-mg limit in daily sodium intake is mandatory in the treatment 
of ascites
• Fluid restriction recommend only when the serum sodium 
concentration is less than 120 mmol per liter. 
http://www.nejm.org/doi/full/10.1056/NEJMra1504367
Management 
Medications: Antihypertensive and Hypertensive Agents
• Nonselective beta-blockers reduce portal pressures and are used in 
the primary and secondary prophylaxis of variceal hemorrhage 
• Antihypertensive agents should be discontinued in patients who have 
decompensated cirrhosis with ascites or hypotension 
• In patients with stable hypotension, midodrine may improve 
splanchnic and systemic hemodynamic variables, renal function, and 
sodium excretion
• The combination of octreotide and midodrine is used for the 
treatment of type 1 hepatorenal syndrome; type 1 hepatorenal 
syndrome is defined as at least a twofold increase in serum creatinine 
(reflecting a 50 percent reduction in creatinine clearance) to a level 
greater than 2.5 mg/dL (221 micromol/L) during a period of less than 
two weeks.
http://www.nejm.org/doi/full/10.1056/NEJMra1504367
Management 
Medications: Pain Management
• Because of the risk of acute renal failure and gastrointestinal 
bleeding, nonsteroidal antiinflammatory drugs are contraindicated, 
except for low-dose aspirin in patients in whom the severity of 
cardiovascular disease exceeds the severity of cirrhosis
• Opiates should be used cautiously or avoided, because they may 
precipitate or aggravate hepatic encephalopathy 
• Acetaminophen is effective and safe in patients with liver disease, 
provided that the patient does not drink alcohol. 
http://www.nejm.org/doi/full/10.1056/NEJMra1504367
Management 
Medications: Proton-Pump Inhibitors
• Proton-pump inhibitors are vastly overprescribed in hospitalized 
patients with cirrhosis, often without any documented indication
• A large study involving patients with cirrhosis who were hospitalized 
with an initial infection showed that the risk of subsequent infection 
was increased among patients taking proton-pump inhibitors and 
those receiving long-term antibiotic agents as prophylaxis for 
spontaneous bacterial peritonitis
• Indiscriminate use without appropriate indications should be 
avoided.
http://www.nejm.org/doi/full/10.1056/NEJMra1504367
Management 
Medications: Sedatives
• Benzodiazepines should be avoided in patients with hepatic 
encephalopathy
• For patients with alcoholic hepatitis or cirrhosis in whom severe 
symptoms of acute alcohol withdrawal develop, short-acting 
benzodiazepines such as lorazepam and oxazepam are preferred in 
order to minimize the risk of oversedation
• For patients with insomnia, hydroxyzine at a dose of 25 mg at 
bedtime may be a reasonable alternative and has been studied in a 
small, randomized trial. 
http://www.nejm.org/doi/full/10.1056/NEJMra1504367
Management 
Medications: Statins
• 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) 
can be safely started and continued in patients with cirrhosis
• Statins have established cardiovascular benefits in the treatment of 
nonalcoholic fatty liver disease
• The overall rate of statin-induced acute liver failure is 0.2 to 1 cases 
per million persons taking statins, although estimates of patients who 
do not receive statins because of concerns about hepatotoxicity 
range from 10 to 30%
• Data from the Drug-Induced Liver Injury Network corroborated the 
exceedingly low likelihood of hepatic injury due to statins, with only 
22 cases of drug-induced liver injury being attributed to statins over 
an 8-year period.
http://www.nejm.org/doi/full/10.1056/NEJMra1504367
Management 
Medications: Vaptans
• Selective vasopressin V2–receptor antagonists (vaptans) have been 
evaluated for use in hyponatremia and ascites
• A large, placebo-controlled study involving patients with cirrhosis and 
ascites showed that although satavaptan alleviated hyponatremia, 
mortality was higher among patients with recurrent ascites who were 
receiving satavaptan than among those who were receiving placebo
• Because of these findings as well as hepatotoxicity reported with 
respect to tolvaptan, the use of vaptans in patients with cirrhosis and 
ascites is not recommended.
http://www.nejm.org/doi/full/10.1056/NEJMra1504367
Management 
Medications: Paracentesis
• Paracentesis is particularly helpful in all patients with new-onset 
ascites, in patients with existing ascites who are admitted to the 
hospital, and in patients with clinical deterioration (fever, abdominal 
pain, hepatic encephalopathy, leukocytosis, renal failure, or 
metabolic acidosis)
• Spontaneous bacterial peritonitis is diagnosed when the neutrophil 
count in ascitic fluid is at least 250 cells per cubic millimeter and 
secondary bacterial peritonitis is ruled out.
http://www.nejm.org/doi/full/10.1056/NEJMra1504367
Management 
Medications: Transplantation
• If complications cannot be controlled or when the liver ceases 
functioning, liver transplantation is necessary
• Survival from liver transplantation has been improving over the 
1990s, and the five-year survival rate is now around 80%
• The survival rate depends largely on the severity of disease and other 
medical problems in the recipient
• In the United States, the MELD score is used to prioritize patients for 
transplantation
• Transplantation necessitates the use of immune suppressants 
(ciclosporin or tacrolimus).
https://en.wikipedia.org/wiki/Cirrhosis
Management 
Medications: Decompensated Cirrhosis
• In patients with previously stable cirrhosis, decompensation may 
occur due to various causes, such as constipation, infection (of any 
source), increased alcohol intake, medication, bleeding from 
esophageal varices or dehydration 
• Patients with decompensated cirrhosis generally require admission 
to hospital, with close monitoring of the fluid balance, mental status, 
and emphasis on adequate nutrition and medical treatment - often 
with diuretics, antibiotics, laxatives and/or enemas, thiamine and 
occasionally steroids, acetylcysteine and pentoxifylline
• Administration of saline is avoided as it would add to the already high 
total body sodium content that typically occurs in cirrhosis.
https://en.wikipedia.org/wiki/Cirrhosis
Management 
Medications: Palliative Care
• Palliative care focuses on providing patients with relief from the 
symptoms, pain, and stress of a serious illness
• The goal of palliative care is to improve quality of life for both the 
patient and the patient's family and it is appropriate at any stage and 
for any type of cirrhosis
• Because the disease is not curable without a transplant, palliative 
care can also help with discussions regarding the person's wishes 
concerning health care power of attorney, Do Not 
Resuscitate decisions and life support, and potentially hospice 
• Despite proven benefit, people with cirrhosis are rarely referred to 
palliative care.
https://en.wikipedia.org/wiki/Cirrhosis
Management 
Medications: Care Coordination
• Patients with cirrhosis are plagued by frequent hospital readmissions 
for fluid overload, hepatic encephalopathy, or gastrointestinal 
hemorrhage
• Such readmissions are costly, moderately predictable, frequently 
preventable, and associated with a risk of death
• Care coordination is an increasingly popular concept to improve 
quality and clinical outcomes while reducing readmission rates and 
expenditures
• Care coordinators facilitate inpatient-to-clinic transitions, reconcile 
medications, call patients to prevent unnecessary visits to the 
emergency department, place “smart scales” in homes to monitor 
body weight remotely, facilitate interaction with other health care 
professionals, and arrange referrals to nursing facilities or hospice.
http://www.nejm.org/doi/full/10.1056/NEJMra1504367
Prognosis
• Prognosis depends on the underlying cause and on the success of its 
treatment
• If someone with alcoholic cirrhosis continues to drink alcohol, the 
rate of decompensation can be rapid
• Patients with fulminant hepatic failure have a 50-80% mortality rate 
unless they receive a liver transplant.
http://patient.info/doctor/cirrhosis-pro
Prophylaxis
• Worldwide, the most important factor in prevention of cirrhosis 
is immunisation against hepatitis B 
• There is no vaccine against hepatitis C but some treatments may 
delay progression and alcohol must be avoided 
• Sensible drinking is essential for everyone and patients should be 
advised about the recommended limits 
• Beware of hepatotoxic medications, including herbal remedies 
• Weight reduction and exercise can improve liver function in patients 
with NAFLD.
http://patient.info/doctor/cirrhosis-pro
Abbreviations 
ALT - alanine aminotransferase 
ALP - alkaline phosphatase 
AST - aspartate aminotransferase 
CH - Cirrhosis of the Liver
HSCs - hepatic stellate cells 
HVPG - hepatic venous pressure gradient 
EGD - esophagogastroduodenoscopy 
FHF - fulminant hepatic failure 
INR - international normalized ratio 
NAFLD - non-alcoholic fatty liver disease
miRNA - a small non-coding RNA molecule
PT - prothrombin time 
PTT - partial thromboplastin time 
Diagnostic and treatment guidelines
Cirrhosis: Diagnosis, Management, and Prevention
NICE Guideline on Cirrhosis (2016)
Guidelines on the management of ascites in cirrhosis
Cirrhosis
